Compare Booz Allen Hamilton Holding Corporation (BAH) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs IDEXX Laboratories, Inc. — how do they compare? Booz Allen Hamilton Holding Corporation trades at $64.49 (market cap $7.62B), while IDEXX Laboratories, Inc. trades at $565.86 (market cap $42.65B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.6× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays a 3.71% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| BAH | IDXX | |
|---|---|---|
Market Cap | $7.62B | $42.65B |
Sector | Industrials | Health |
52-Week High | $115.95 | $766.68 |
52-Week Low | $59.71 | $514.61 |
Enterprise Value | $11.02B | $43.56B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $64.80, up 3.25% in the last session, with a bearish technical signal but strong fundamentals including a P/E of 9.39 and net income margin of 7.59%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. The company announced a partnership with OpenAI and an acquisition to bolster its defense technology portfolio, signaling strategic growth in AI and national security sectors.
Outlook is mixed: analyst consensus price target of $78.17 suggests 20% upside, supported by robust cash flow and government contracts, but risks include high debt levels and market volatility. The stock's current price near the low end of analyst targets indicates potential value, though technical indicators warn of short-term pressure.
IDXX trades at $564.09, up 0.09% with neutral technical signals. The stock shows strong fundamentals with revenue growth to $4.3B in 2025 and consistent earnings beats. Analyst consensus is bullish (59% Buy) with improving cash flow trends. Recent news highlights AI integration in medical devices and upcoming Q2 2026 earnings.
Outlook remains positive driven by innovation and market leadership in pet healthcare. Risks include high valuation multiples and competitive pressures. Institutional sentiment supports growth, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
